NASDAQ:HALO - Halozyme Therapeutics Stock Price, Price Target & More

Get Started

$18.76 +0.52 (+2.85 %)

(As of 05/24/2018 05:23 AM ET)

Previous Close$18.24

Today's Range$18.18 - $18.82

52-Week Range$11.41 - $21.48

Volume546,840 shs

Average Volume963,335 shs

Market Capitalization$2.63 billion

P/E Ratio40.53

Dividend YieldN/A

Beta1.88

About Halozyme Therapeutics (NASDAQ:HALO)

Halozyme Therapeutics, Inc., a biotechnology company, researches, develops, and commercializes human enzymes and other drug candidates in the United States, Switzerland, and internationally. The company's human enzymes are used to facilitate the delivery of injected drugs and fluids, enhancing the efficacy and the convenience of other drugs or can be used to alter tissue structures for clinical benefit. Its products are based on the Enhanze technology, a patented recombinant human hyaluronidase enzyme (rHuPH20) that enables the subcutaneous delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids. The company's pipeline include Hylenex recombinant, a formulation of rHuPH20 to facilitate subcutaneous fluid administration for achieving hydration; to enhance the dispersion and absorption of other injected drugs; in subcutaneous urography; and to enhance resorption of radiopaque agents. It also develops PEGylated recombinant human hyaluronidase for the treatment of pancreatic ductal adenocarcinoma, non-small cell lung cancer, gastric cancer, metastatic breast cancer, and cholangiocarcinoma and gall bladder cancer. In addition, the company develops PEGylated adenosine deaminase 2, an immune checkpoint inhibitor that targets adenosine. It has collaborations with F. Hoffmann-La Roche, Ltd.; Hoffmann-La Roche, Inc.; Baxalta US Inc.; Baxalta GmbH; Pfizer Inc.; Janssen Biotech, Inc.; AbbVie, Inc.; Eli Lilly and Company; Bristol-Myers Squibb Company; and Alexion Pharma Holding. Halozyme Therapeutics, Inc. was founded in 1998 and is headquartered in San Diego, California.

Receive HALO News and Ratings via Email

Sign-up to receive the latest news and ratings for HALO and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Biological products, except diagnostic

Sub-IndustryBiotechnology

SectorMedical

SymbolNASDAQ:HALO

CUSIP40637H10

Webwww.halozyme.com

Phone858-794-8889

Debt

Debt-to-Equity Ratio0.39

Current Ratio4.06

Quick Ratio4.03

Price-To-Earnings

Trailing P/E Ratio40.53

Forward P/E Ratio-20.39

P/E GrowthN/A

Sales & Book Value

Annual Sales$316.61 million

Price / Sales8.53

Cash Flow$0.4683 per share

Price / Cash40.06

Book Value$1.84 per share

Price / Book10.20

Profitability

EPS (Most Recent Fiscal Year)$0.45

Net Income$62.97 million

Net Margins21.52%

Return on Equity45.31%

Return on Assets15.93%

Miscellaneous

Employees255

Outstanding Shares143,970,000

Halozyme Therapeutics (NASDAQ:HALO) Frequently Asked Questions

What is Halozyme Therapeutics' stock symbol?

Halozyme Therapeutics trades on the NASDAQ under the ticker symbol "HALO."

How were Halozyme Therapeutics' earnings last quarter?

Halozyme Therapeutics, Inc. (NASDAQ:HALO) released its quarterly earnings data on Thursday, May, 10th. The biopharmaceutical company reported ($0.19) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.22) by $0.03. The biopharmaceutical company had revenue of $30.90 million for the quarter, compared to analysts' expectations of $31.84 million. Halozyme Therapeutics had a return on equity of 45.31% and a net margin of 21.52%. The firm's quarterly revenue was up 4.4% on a year-over-year basis. During the same period in the prior year, the firm posted ($0.26) EPS. View Halozyme Therapeutics' Earnings History.

When is Halozyme Therapeutics' next earnings date?

Halozyme Therapeutics is scheduled to release their next quarterly earnings announcement on Monday, August, 6th 2018. View Earnings Estimates for Halozyme Therapeutics.

What price target have analysts set for HALO?

8 analysts have issued twelve-month price objectives for Halozyme Therapeutics' stock. Their forecasts range from $7.00 to $29.00. On average, they anticipate Halozyme Therapeutics' share price to reach $19.75 in the next year. View Analyst Ratings for Halozyme Therapeutics.

Who are some of Halozyme Therapeutics' key competitors?

Some companies that are related to Halozyme Therapeutics include bluebird bio (BLUE), Seattle Genetics (SGEN), Neurocrine Biosciences (NBIX), Qiagen (QGEN), AveXis (AVXS), Bio-Techne (TECH), arGEN-X BV (ARGX), CRISPR Therapeutics (CRSP), Spark Therapeutics (ONCE), China Biologic Products (CBPO), Atara Biotherapeutics (ATRA), Aerie Pharmaceuticals (AERI), Denali Therapeutics (DNLI), Repligen (RGEN) and Momenta Pharmaceuticals (MNTA).

Who are Halozyme Therapeutics' key executives?

Halozyme Therapeutics' management team includes the folowing people:

Dr. Helen I. Torley, Pres, CEO & Director (Age 55)
Ms. Laurie D. Stelzer, Sr. VP & CFO (Age 50)
Mr. Harry J. Leonhardt, Sr. VP, Gen. Counsel, Chief Compliance Officer & Corp. Sec. (Age 61)
Mr. Mark J. Gergen, Former Chief Operating Officer (Age 55)
Dr. Michael J. LaBarre Ph.D., Chief Scientific Officer and VP (Age 54)

Has Halozyme Therapeutics been receiving favorable news coverage?

News coverage about HALO stock has trended somewhat positive on Thursday, according to Accern Sentiment Analysis. The research firm identifies positive and negative media coverage by monitoring more than 20 million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. Halozyme Therapeutics earned a media sentiment score of 0.06 on Accern's scale. They also assigned news stories about the biopharmaceutical company an impact score of 46.61 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the stock's share price in the near future.

Who are Halozyme Therapeutics' major shareholders?

Halozyme Therapeutics' stock is owned by a number of of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (8.06%), Iridian Asset Management LLC CT (5.70%), JPMorgan Chase & Co. (2.17%), First Eagle Investment Management LLC (2.09%), Artisan Partners Limited Partnership (1.18%) and Northern Trust Corp (1.15%). View Institutional Ownership Trends for Halozyme Therapeutics.

Which major investors are selling Halozyme Therapeutics stock?

HALO stock was sold by a variety of institutional investors in the last quarter, including First Eagle Investment Management LLC, Iridian Asset Management LLC CT, BlackRock Inc., Rubric Capital Management LP, Russell Investments Group Ltd., American Century Companies Inc., Millennium Management LLC and A.R.T. Advisors LLC. View Insider Buying and Selling for Halozyme Therapeutics.

Which major investors are buying Halozyme Therapeutics stock?

HALO stock was bought by a variety of institutional investors in the last quarter, including Prudential Financial Inc., Dimensional Fund Advisors LP, Schwab Charles Investment Management Inc., Alambic Investment Management L.P., Victory Capital Management Inc., GSA Capital Partners LLP, UBS Group AG and Federated Investors Inc. PA. View Insider Buying and Selling for Halozyme Therapeutics.

How do I buy shares of Halozyme Therapeutics?

Shares of HALO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Halozyme Therapeutics' stock price today?

One share of HALO stock can currently be purchased for approximately $18.76.

How big of a company is Halozyme Therapeutics?

Halozyme Therapeutics has a market capitalization of $2.63 billion and generates $316.61 million in revenue each year. The biopharmaceutical company earns $62.97 million in net income (profit) each year or $0.45 on an earnings per share basis. Halozyme Therapeutics employs 255 workers across the globe.

How can I contact Halozyme Therapeutics?

Halozyme Therapeutics' mailing address is 11388 SORRENTO VALLEY ROAD, SAN DIEGO CA, 92121. The biopharmaceutical company can be reached via phone at 858-794-8889 or via email at [email protected]

MarketBeat Community Rating for Halozyme Therapeutics (HALO)

Community Ranking:		2.8 out of 5 ( )
Outperform Votes:		278 (Vote Outperform)
Underperform Votes:		223 (Vote Underperform)
Total Votes:		501

MarketBeat's community ratings are surveys of what our community members think about Halozyme Therapeutics and other stocks. Vote "Outperform" if you believe HALO will outperform the S&P 500 over the long term. Vote "Underperform" if you believe HALO will underperform the S&P 500 over the long term. You may vote once every thirty days.

Halozyme Therapeutics (NASDAQ:HALO) Price Target and Consensus Rating

(How are Consensus Ratings Calculated?)

8 Wall Street analysts have issued ratings and price targets for Halozyme Therapeutics in the last 12 months. Their average twelve-month price target is $19.75, suggesting that the stock has a possible upside of 5.28%. The high price target for HALO is $29.00 and the low price target for HALO is $7.00. There are currently 2 sell ratings, 2 hold ratings and 4 buy ratings for the stock, resulting in a consensus rating of "Hold."

	Today	30 Days Ago	90 Days Ago	180 Days Ago
Consensus Rating:	Hold	Hold	Hold	Hold
Consensus Rating Score:	2.25	2.38	2.38	2.29
Ratings Breakdown:	2 Sell Rating(s) 2 Hold Rating(s) 4 Buy Rating(s) 0 Strong Buy Rating(s)	1 Sell Rating(s) 3 Hold Rating(s) 4 Buy Rating(s) 0 Strong Buy Rating(s)	1 Sell Rating(s) 3 Hold Rating(s) 4 Buy Rating(s) 0 Strong Buy Rating(s)	1 Sell Rating(s) 3 Hold Rating(s) 3 Buy Rating(s) 0 Strong Buy Rating(s)
Consensus Price Target:	$19.75	$19.75	$19.75	$18.00
Price Target Upside:	5.28% upside	2.65% upside	2.65% upside	6.25% downside

Halozyme Therapeutics (NASDAQ:HALO) Consensus Price Target History

Price Target History for Halozyme Therapeutics (NASDAQ:HALO)

Halozyme Therapeutics (NASDAQ:HALO) Analyst Ratings History

Show:

Date	Brokerage	Action	Rating	Price Target	Impact on Share Price
5/11/2018	Barclays	Downgrade	Equal Weight ➝ Underweight	$19.00	High
2/22/2018	BMO Capital Markets	Reiterated Rating	Market Perform ➝ Market Perform	$18.00 ➝ $19.00	Low
2/21/2018	Canaccord Genuity	Boost Price Target	Buy	$19.00 ➝ $21.00	High
2/21/2018	JPMorgan Chase & Co.	Reiterated Rating	Overweight ➝ Overweight	$19.00 ➝ $22.00	Low
1/24/2018	Deutsche Bank	Set Price Target	Buy	$21.00	Low
1/24/2018	Goldman Sachs Group	Initiated Coverage	Neutral ➝ Neutral	$20.00	High
10/16/2017	Piper Jaffray Companies	Boost Price Target	Overweight ➝ Overweight	$26.00 ➝ $29.00	N/A
8/10/2017	Jefferies Group	Reiterated Rating	Underperform	$6.75 ➝ $7.00	High
1/6/2017	Citigroup	Downgrade	Buy ➝ Neutral		N/A
9/8/2016	Wells Fargo & Co	Reiterated Rating	Buy		N/A

(Data available from 5/24/2016 forward)

Halozyme Therapeutics (NASDAQ:HALO) Earnings History and Estimates Chart

Earnings by Quarter for Halozyme Therapeutics (NASDAQ:HALO)

Halozyme Therapeutics (NASDAQ:HALO) Earnings Estimates

2018 EPS Consensus Estimate: ($1.05)

Quarter	Number of Estimates	Low Estimate	High Estimate	Average Estimate
Q1 2018	1	($0.28)	($0.28)	($0.28)
Q2 2018	1	($0.27)	($0.27)	($0.27)
Q3 2018	1	($0.26)	($0.26)	($0.26)
Q4 2018	1	($0.24)	($0.24)	($0.24)

Halozyme Therapeutics (NASDAQ HALO) Earnings History by Quarter

Date	Quarter	Consensus Estimate	Actual EPS	Revenue Estimate	Actual Revenue	Release Link	Conference Call
8/6/2018		($0.22)					N/A
5/10/2018	Q1 2018	($0.22)	($0.19)	$31.84 million	$30.90 million	View	N/A
2/20/2018	Q4 2017	$0.58	$0.85	$173.11 million	$189.60 million	View	Listen
11/7/2017	Q3 2017	$0.06	$0.0190	$58.95 million	$63.73 million	View	N/A
8/8/2017	Q2 2017	($0.25)	($0.23)	$31.76 million	$33.80 million	View	Listen
5/9/2017	Q1 2017	($0.25)	($0.26)	$30.79 million	$29.60 million	View	Listen
2/28/2017	Q416	($0.30)	($0.21)	$37.94 million	$39.00 million	View	Listen
11/7/2016	Q316	($0.27)	($0.23)	$34.43 million	$31.90 million	View	Listen
8/9/2016	Q216	($0.27)	($0.21)	$29.94 million	$33.30 million	View	N/A
5/9/2016	Q116	($0.20)	($0.16)	$29.65 million	$42.50 million	View	N/A
2/29/2016	Q415	($0.08)	$0.03	$37.06 million	$52.20 million	View	Listen
11/9/2015	Q315	($0.16)	($0.19)	$24.01 million	$20.80 million	View	N/A
8/10/2015	Q215	($0.09)	$0.02	$24.84 million	$43.40 million	View	Listen
5/11/2015	Q115	($0.13)	($0.12)	$19.40 million	$18.70 million	View	Listen
3/2/2015	Q414	($0.07)	($0.04)	$25.60 million	$30.38 million	View	N/A
11/10/2014	Q314	($0.14)	($0.16)	$16.50 million	$14.60 million	View	N/A
8/11/2014	Q214	($0.18)	($0.13)	$13.71 million	$18.40 million	View	N/A
5/12/2014	Q114	($0.14)	($0.22)	$13.37 million	$12.00 million	View	N/A
2/27/2014	Q413	($0.17)	($0.19)	$21.80 million	$12.50 million	View	N/A
11/8/2013	Q313	($0.15)	($0.17)	$14.62 million	$16.00 million	View	N/A
8/7/2013	Q2 2013	($0.13)	($0.13)	$11.29 million	$14.50 million	View	N/A
5/8/2013	Q1 2013	($0.15)	($0.17)	$7.05 million	$11.83 million	View	N/A
2/25/2013	Q4 2012	($0.16)	($0.04)	$7.32 million	$21.80 million	View	N/A
11/8/2012	Q312	($0.13)	($0.18)	$6.09 million	$5.33 million	View	N/A
8/6/2012		($0.15)	($0.13)			View	N/A
5/7/2012		($0.11)	$0.14			View	N/A
3/9/2012		($0.16)	($0.18)			View	N/A
11/7/2011		($0.03)	$0.05			View	N/A
8/5/2011	Q2 2011	($0.13)	$0.03			View	N/A
5/6/2011	Q1 2011	($0.13)	($0.10)			View	N/A
3/11/2011	Q4 2010	($0.12)	($0.17)			View	N/A
11/5/2010	Q3 2010	($0.13)	($0.13)			View	N/A
8/6/2010	Q2 2010	($0.14)	($0.13)			View	N/A
5/7/2010	Q1 2010	($0.16)	($0.13)			View	N/A
3/12/2010	Q4 2009	($0.16)	($0.14)			View	N/A
11/6/2009	Q3 2009	($0.18)	($0.16)			View	N/A
8/7/2009	Q2 2009	($0.16)	($0.21)			View	N/A
5/8/2009	Q1 2009	($0.15)	($0.18)			View	N/A
3/13/2009	Q4 2008	($0.13)	($0.21)			View	N/A
11/6/2008	Q3 2008	($0.14)	($0.14)			View	N/A
8/8/2008	Q2 2008	($0.13)	($0.14)			View	N/A
5/8/2008	Q1 2008	($0.12)	($0.13)			View	N/A
3/13/2008	Q4 2007	($0.09)	($0.11)			View	N/A

(Earnings results data provided by Zacks Investment Research)

Halozyme Therapeutics (NASDAQ:HALO) Dividend History by Quarter

Announced	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date

(Data available from 1/1/2013 forward)

Halozyme Therapeutics (NASDAQ HALO) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 16.80%
Institutional Ownership Percentage: 84.96%

Insider Trading History for Halozyme Therapeutics (NASDAQ:HALO)

Institutional Ownership by Quarter for Halozyme Therapeutics (NASDAQ:HALO)

Halozyme Therapeutics (NASDAQ HALO) Insider Trading History

Transaction Date	Insider Name	Title	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
8/20/2015	Laurie Stelzer	CFO	Buy	10,000	$17.24	$172,400.00
6/18/2015	Kenneth J Kelley	Director	Sell	20,000	$21.00	$420,000.00
9/16/2014	David A Ramsay	CFO	Buy	25,000	$8.90	$222,500.00
9/16/2014	Helen Torley	CEO	Buy	50,000	$8.92	$446,000.00
8/19/2014	John Stuart Patton	Director	Sell	75,000	$9.96	$747,000.00
5/15/2014	Robert Engler	Director	Sell	126,700	$7.56	$957,852.00	233,176
9/16/2013	John Stuart Patton	Director	Sell	75,000	$9.13	$684,750.00	155,000
8/19/2013	H. Michael Shepard	VP	Sell	10,000	$7.11	$71,100.00
8/14/2013	Kathryn Falberg	Director	Buy	100,000	$6.82	$682,000.00	280,000
11/29/2012	Robert Engler	Director	Buy	15,000	$5.57	$83,550.00
11/14/2012	James P Shaffer	VP	Buy	20,000	$5.22	$104,400.00
11/13/2012	Kathryn E Falberg	Director	Buy	50,000	$5.21	$260,500.00
8/27/2012	Kenneth J Kelley	Director	Buy	20,000	$5.70	$114,000.00
8/13/2012	Gregory Ian Frost	CEO	Buy	2,000	$5.50	$11,000.00

(Data available from 1/1/2013 forward)

Halozyme Therapeutics (NASDAQ HALO) News Headlines

Source:

Date	Headline
	Halozyme (HALO) Downgraded by BidaskClub www.americanbankingnews.com - May 18 at 3:09 PM
	Halozyme, Inc. (HALO) Expected to Announce Quarterly Sales of $30.90 Million www.americanbankingnews.com - May 18 at 4:24 AM
	Halozyme (HALO) Downgraded by ValuEngine to "Hold" www.americanbankingnews.com - May 17 at 10:54 PM
	TheStreet Lowers Halozyme (HALO) to C www.americanbankingnews.com - May 17 at 3:27 PM
	Brokerages Anticipate Halozyme, Inc. (HALO) to Announce -$0.23 Earnings Per Share www.americanbankingnews.com - May 16 at 12:42 PM
	Today's Research Reports on Trending Tickers: OPKO Health and Halozyme Therapeutics finance.yahoo.com - May 15 at 8:50 AM
	Halozyme (HALO) Cut to Underweight at Barclays www.americanbankingnews.com - May 11 at 6:33 PM
	Halozyme (HALO) Posts Earnings Results, Beats Estimates By $0.03 EPS www.americanbankingnews.com - May 11 at 2:50 PM
	Halozyme Therapeutics' (HALO) CEO Helen Torley on Q1 2018 Results - Earnings Call Transcript seekingalpha.com - May 11 at 8:56 AM
	Edited Transcript of HALO earnings conference call or presentation 10-May-18 8:30pm GMT finance.yahoo.com - May 11 at 8:56 AM
	BRIEF-Halozyme Reports Q1 Loss Per Share $0.19 www.reuters.com - May 10 at 5:37 PM
	Halozyme Reports First Quarter 2018 Results finance.yahoo.com - May 10 at 5:37 PM
	Halozyme Therapeutics: 1Q Earnings Snapshot finance.yahoo.com - May 10 at 5:37 PM
	Halozyme (HALO) Upgraded to Buy by ValuEngine www.americanbankingnews.com - May 3 at 4:24 PM
	Form 4 HALOZYME THERAPEUTICS For: May 02 Filed by: Henderson Jeffrey William www.streetinsider.com - May 3 at 8:31 AM
	Halozyme Sees Unusually Large Options Volume (HALO) www.americanbankingnews.com - May 1 at 7:16 AM
	Halozyme (HALO) to Release Earnings on Monday www.americanbankingnews.com - April 30 at 5:22 AM
	Halozyme, Inc. (HALO) Expected to Post Quarterly Sales of $29.21 Million www.americanbankingnews.com - April 30 at 2:10 AM
	Halozyme, Inc. (HALO) Receives Average Rating of "Hold" from Analysts www.americanbankingnews.com - April 29 at 5:57 PM
	Halozyme, Inc. (HALO) Expected to Announce Earnings of -$0.21 Per Share www.americanbankingnews.com - April 28 at 9:14 PM
	MabVax Therapeutics (MBVX) Announces Results of Antibody Program in Three Poster Presentations at 2018 AACR Meetings www.streetinsider.com - April 19 at 8:33 AM
	Canaccord Genuity Analysts Give Halozyme Therapeutics (HALO) a $16.00 Price Target www.americanbankingnews.com - April 15 at 8:22 PM
	Zacks: Brokerages Anticipate Halozyme Therapeutics, Inc. (HALO) Will Post Quarterly Sales of $29.54 Million www.americanbankingnews.com - April 13 at 1:58 AM
	Halozyme Therapeutics, Inc. (HALO) Expected to Post Earnings of -$0.21 Per Share www.americanbankingnews.com - April 11 at 9:16 PM
	Piper Jaffray Analysts Give Halozyme Therapeutics (HALO) a $20.00 Price Target www.americanbankingnews.com - April 10 at 10:31 PM
	Abzena Notes Termination Of Agreement With Halozyme Therapeutics www.lse.co.uk - April 10 at 8:49 AM
	Halozyme To Host First Quarter 2018 Financial Results Conference Call finance.yahoo.com - April 10 at 8:49 AM
	BRIEF-Abzena Gets Notice From Halozyme Of Termination Of Agreement www.reuters.com - April 9 at 8:44 AM
	Form DEFA14A HALOZYME THERAPEUTICS www.streetinsider.com - April 6 at 5:26 PM
	Halozyme Therapeutics, Inc. (HALO) Given Consensus Rating of "Hold" by Brokerages www.americanbankingnews.com - April 4 at 5:38 PM
	Halozyme Therapeutics (HALO) PT Raised to $18.00 www.americanbankingnews.com - April 1 at 9:46 AM
	Halozyme Therapeutics (HALO) Cut to "Hold" at BidaskClub www.americanbankingnews.com - March 30 at 2:18 PM
	$29.54 Million in Sales Expected for Halozyme Therapeutics, Inc. (HALO) This Quarter www.americanbankingnews.com - March 27 at 1:56 AM
	Halozyme Therapeutics (HALO) Upgraded to Buy by Zacks Investment Research www.americanbankingnews.com - March 26 at 5:58 PM
	Zacks: Analysts Expect Halozyme Therapeutics, Inc. (HALO) to Announce -$0.21 Earnings Per Share www.americanbankingnews.com - March 25 at 11:14 PM
	Halozyme Therapeutics (HALO) and Eisai (ESALY) Head-To-Head Survey www.americanbankingnews.com - March 24 at 7:14 AM
	Halozyme Therapeutics (HALO) Upgraded by TheStreet to "B-" www.americanbankingnews.com - March 24 at 12:28 AM
	Halozyme Therapeutics (HALO) Raised to Strong-Buy at BidaskClub www.americanbankingnews.com - March 23 at 7:56 PM
	SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces an Investigation Concerning Possible Breaches of Fiduciary Duty by Certain Officers and Directors of Halozyme Therapeutics, Inc. finance.yahoo.com - March 23 at 8:40 AM
	Halozyme Announces Nomination Of Directors For Reelection At 2018 Stockholder Meeting finance.yahoo.com - March 22 at 5:23 PM
	Halozyme Therapeutics (HALO) to Present Data From Six ... - StreetInsider.com www.streetinsider.com - March 16 at 8:38 AM
	Halozyme Therapeutics (HALO) to Present Data From Six Nonclinical Studies at AACR www.streetinsider.com - March 15 at 8:34 AM
	Halozyme To Present Data From Six Nonclinical Studies At American Association Of Cancer Research Annual Conference finance.yahoo.com - March 14 at 6:46 PM
	Global Antidiabetics Market Opportunities 2018: Eli Lilly, Boehringer Ingelheim, Novo Nordisk www.marketwatch.com - March 14 at 9:00 AM
	QCOM Jeffrey William Henderson Insider Trades for Qualcomm Inc. www.marketwatch.com - March 13 at 7:05 PM
	Halozyme Therapeutics, Inc. (HALO) Receives Consensus Rating of "Hold" from Brokerages www.americanbankingnews.com - March 10 at 5:41 PM
	Analysts Anticipate Halozyme Therapeutics, Inc. (HALO) to Post -$0.20 Earnings Per Share www.americanbankingnews.com - March 8 at 4:15 PM
	Senzar Asset Management LLC Has $10.89 Million Position in Halozyme Therapeutics, Inc. (HALO) www.americanbankingnews.com - March 5 at 3:44 PM
	Halozyme Therapeutics, Inc. (HALO) Shares Sold by Kennedy Capital Management Inc. www.americanbankingnews.com - March 5 at 11:39 AM
	97,707 Shares in Halozyme Therapeutics, Inc. (HALO) Purchased by Schroder Investment Management Group www.americanbankingnews.com - March 5 at 9:40 AM

Halozyme Therapeutics (NASDAQ:HALO) SEC Filings

Form Type:

Ownership Filings:

This page is loading this company's SEC Filings. Please wait...

Halozyme Therapeutics (NASDAQ:HALO) Income Statement, Balance Sheet and Cash Flow Statement

Halozyme Therapeutics (NASDAQ HALO) Stock Chart for Thursday, May, 24, 2018

Loading chart…

This page was last updated on 5/24/2018 by MarketBeat.com Staff